ArticleScientific reports2017
The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 77 citations in OpenAlex.
- Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults.Scientific reports · 2021Trial
- Multifunctional biotherapeutic probiotic bacteria with antioxidant capacity for cholesterol reduction, and inflammation alleviation.Folia microbiologica · 2026Article
- Lactobacillus plantarum and Lactobacillus acidophilus enhance growth performance, immunity, cecal microbiota, and vital organs histomorphology in rabbits.Scientific reports · 2026Article
- The impact of the Lab4 probiotic on neurodegenerative processes in a murine Alzheimer's disease model.Frontiers in neuroscience · 2026Article
- Probiotics in atherosclerosis: mechanisms, efficacy and future directions - a review study.Frontiers in immunology · 2026Review
- Assessment of multi-strain probiotics in regulating diet-induced obesity in Balb/c mice model.International journal of obesity (2005) · 2026Article
- Gut microbiota-cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation.Nutrition & metabolism · 2025Review
- Polyphenol-Microbiota Interactions in Atherosclerosis: The Role of Hydroxytyrosol and Tyrosol in Modulating Inflammation and Oxidative Stress.Nutrients · 2025Review
- Review
- Investigation of new exopolysaccharides produced by strains of donkey milk.Iranian journal of microbiology · 2025Article
- Potential effects of probiotics on atherosclerosis.Microbiome research reports · 2025Review
- Advances in Microbial Exopolysaccharides: Present and Future Applications.Biomolecules · 2024Review
- Targeting Gut Microbiota with Probiotics and Phenolic Compounds in the Treatment of Atherosclerosis: A Comprehensive Review.Foods (Basel, Switzerland) · 2024Review
- Impact of Oral Administration ofBioengineering (Basel, Switzerland) · 2023Article
- Effects of Probiotic Supplementation on Exercise and the Underlying Mechanisms.Foods (Basel, Switzerland) · 2023Review
- Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer's Disease Model Mice and the SH-SY5Y Neuronal Cell Line.International journal of molecular sciences · 2023Article
- Anti-Atherogenic Actions of the Lab4b Consortium of Probiotics In Vitro.International journal of molecular sciences · 2023Article
- Mitochondria as novel mediators linking gut microbiota to atherosclerosis that is ameliorated by herbal medicine: A review.Frontiers in pharmacology · 2023Review
- Genomic analysis and in vivo efficacy of Pediococcus acidilactici as a potential probiotic to prevent hyperglycemia, hypercholesterolemia and gastrointestinal infections.Scientific reports · 2022Article
- The role of the gut microbiota in health and cardiovascular diseases.Molecular biomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercholesterolaemia is a major risk factor for cardiovascular disease and it has been found that some probiotic bacteria possess cholesterol-lowering capabilities. In this study, the ability of the Lab4 probiotic consortium to hydrolyse bile salts, assimilate cholesterol and regulate cholesterol transport by polarised Caco-2 enterocytes was demonstrated. Furthermore, in wild-type C57BL/6J mice fed a high fat diet, 2-weeks supplementation with Lab4 probiotic consortium plus Lactobacillus plantarum CUL66 resulted in significant reductions in plasma total cholesterol levels and suppression of diet-induced weight gain. No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, high-density lipoprotein, triglycerides, cytokines or bile acids were observed. Increased amounts of total and unconjugated bile acids in the faeces of the probiotic-fed mice, together with modulation of hepatic small heterodimer partner and cholesterol-7α-hydroxylase mRNA expression, implicates bile salt hydrolase activity as a potential mechanism of action. In summary, this study demonstrates the cholesterol-lowering efficacy of short-term feeding of the Lab4 probiotic consortium plus L. plantarum CUL66 in wild-type mice and supports further assessment in human trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.